發(fā)布時(shí)間：2018-01-31 21:11

  本文關(guān)鍵詞： 常染色體顯性多囊腎病 二肽基肽酶 腺苷磷酸活化蛋白激酶 哺乳動(dòng)物雷帕霉素靶蛋白　出處：《第二軍醫(yī)大學(xué)》2016年博士論文　論文類(lèi)型：學(xué)位論文

【摘要】：研究背景及目的常染色體顯性多囊腎病(Autosomal dominant polycystic kidney disease, ADPKD)是人類(lèi)發(fā)病率最高的單基因遺傳性腎臟病。接受替代治療的終末期腎病(ESRD)中7-10%是ADPKD患者。盡管在發(fā)現(xiàn)此病500年來(lái)進(jìn)行了大量的研究,直至今日仍然無(wú)法治愈且對(duì)其機(jī)制尚不明了。所有人種皆不能幸免于ADPKD,7-10%的ESRD因此而起。全球范圍,接受腎臟替代治療(RRT)的第四大原因就是ADPKD。在不同的國(guó)家,ADPKD導(dǎo)致的ESRD發(fā)病率有所不同,在日本是每年百萬(wàn)分之4.8,在美國(guó)是每年百萬(wàn)分之7.9,歐洲各國(guó)每年百萬(wàn)分之3.9到15.3。在丹麥哥本哈根[4]和美國(guó)奧姆斯特德進(jìn)行的流行病學(xué)調(diào)查顯示,80歲以下人口中,ADPKD的患病率是400到1000分之一。此后在歐洲和日本進(jìn)行的其他研究顯示不同地區(qū)ADPKD患病率波動(dòng)于543到4000分之一。鑒于上述研究地理位置、觀測(cè)時(shí)間、采樣方法、診斷標(biāo)準(zhǔn)、家系調(diào)查、人口多寡都有不同,故而差異雖大尚可理解。然則,來(lái)自尸檢報(bào)告的數(shù)據(jù)要高于1/500,為1/339-1/492。這說(shuō)明大量患者終其一生未能確診。ADPKD由多囊腎病基因1(Polycystic kidney disease 1 gene, PKD1)和多囊腎病基因2(Polycystic kidney disease 2 gene, PKD2)兩個(gè)基因突變?cè)斐?此二基因分別編碼多囊蛋白-1(Polycystin-1, PC1)及多囊蛋白.2(Polycystin-2, PC2)。其中PKD1突變的患者占80～85%,PKD2突變的患者占15-20%。所謂PKD3,經(jīng)過(guò)對(duì)相關(guān)病例的重新分析,已經(jīng)基本排除了其存在的可能性。PC1與PC2在腎小管上皮細(xì)胞初級(jí)纖毛上相互作用構(gòu)成復(fù)合體,后者屬于瞬時(shí)受體電位(transient receptor potential, T P)家族中的一種非選擇性鈣離子滲透通道。PC1的C末端結(jié)構(gòu)域可以易位至細(xì)胞核的結(jié)構(gòu),并充當(dāng)基因轉(zhuǎn)錄的共激活劑。PC1和PC2在纖毛經(jīng)受機(jī)械刺激時(shí)引發(fā)Ca2+瞬間內(nèi)流。ADPKD的發(fā)病機(jī)制尚未清楚,有前途的治療方法主要集中于通過(guò)阻斷過(guò)度活化mTOR通路和cAMP通路來(lái)延緩疾病進(jìn)展。動(dòng)物實(shí)驗(yàn)發(fā)現(xiàn)mTOR抑制劑(依維莫司和西羅莫司)改善嚙齒類(lèi)動(dòng)物模型囊性腎病的效果非常顯著,但依維莫司和西羅莫司都是強(qiáng)效的免疫抑制劑,可能帶來(lái)致命的副作用,且臨床試驗(yàn)并未取得良好的療效。所以我們需要探索更為安全有效的手段。大量報(bào)道證實(shí)AMP活化蛋白激酶(AMP-activated protein kinase, AMPK)下調(diào)是：mTOR通路過(guò)度活化的原因之一,通過(guò)上調(diào)MPK水平可以抑制過(guò)度活化的mTOR通路,并在動(dòng)物模型中取得了良好的效果。通過(guò)抑制二肽基肽酶4(dipeptidyl peptidase 4, DPP4)的活性可以上調(diào)AMPK水平是毫無(wú)疑問(wèn)的,但能否抑制過(guò)度激活的mTOR通路改善ADPKD, ADPKD患者和動(dòng)物模型中是否存在DPP4過(guò)表達(dá)從而過(guò)度激活了mTOR通路,這兩個(gè)問(wèn)題尚無(wú)解答。本課題的目的是觀察ADPKD患者和實(shí)驗(yàn)動(dòng)物腎組織中DPP4是否存在表達(dá)上調(diào),以及使用DPP4抑制劑,是否能同過(guò)上調(diào)AMPK,抑制mTO R活性,達(dá)到治療ADPKD的目的。研究方法1、DPP4在ADPKD患者及動(dòng)物模型中的表達(dá)水平檢測(cè)：搜集ADPKD患者腎組織與移植供腎組織標(biāo)本,用western blot技術(shù)測(cè)定兩者的DPP4蛋白表達(dá)量,并進(jìn)行比較；繁育多囊腎模型Han:SPRD大鼠,鑒定出野生型(WT)和發(fā)病模型(cy-／+),正常飼養(yǎng)至12周,取腎組織,采用western blot測(cè)定DPP4蛋白表達(dá)量,進(jìn)行比較。2、動(dòng)物實(shí)驗(yàn)驗(yàn)證抑制DPP4活性：干預(yù)藥物包括AMPK激活劑二甲雙胍(Metformin), DPP4抑制劑維格列汀(Vildagliptin)和利格列汀(Linagliptin)。繁育多囊腎模型Han:SPRD大鼠,出生后鑒定出野生型(WT)和發(fā)病模型(cy-/+)。將發(fā)病模型大鼠分為對(duì)照組(Ctrl)以及二甲雙胍(MET)組、維格列汀(VIG)組、利格列汀(LIG)組。后3組大鼠自出生后4周給藥,于第4/8/12周取血查腎功能,第12周代謝籠測(cè)24小時(shí)尿量,并處死動(dòng)物,取雙腎測(cè)腎重體重比,提取蛋白,送病理行全片掃面。3、細(xì)胞實(shí)驗(yàn)觀察抑制DPP4活性對(duì)細(xì)胞增殖的影響：采用人腎囊腫襯里上皮細(xì)胞株WT9.12進(jìn)行培養(yǎng)。以MTT方法觀察在不同濃度的二甲雙胍、維格列汀、利格列汀作用下,24小時(shí)、48小時(shí)、72小時(shí)細(xì)胞增殖情況。4、抑制DPP4活性治療ADPKD的機(jī)制研究：取不同濃度二甲雙胍、維格列汀、利格列汀處理的WT9.12細(xì)胞,Western blot技術(shù)分析干預(yù)后AMPK的蛋白含量變化。取前述實(shí)驗(yàn)提取WT、Ctrl、MET、VIG、LIG組大鼠腎組織蛋白,用western blot技術(shù)測(cè)定AMPK、Akt、p70S6K蛋白含量。研究結(jié)果1、ADPKD患者腎臟組織中DPP4的表達(dá)量顯著高于移植供腎(1.97 vs.0.60,P=0.002),升高了大約3倍。多囊腎模型大鼠(cy-/+)腎臟中情況類(lèi)似,發(fā)病的模型大鼠腎臟中DPP4表達(dá)量升高了接近3倍(7.49 vs 1.14,P=0.001)。2、與對(duì)照組相比,二甲雙胍、維格列汀和利格列汀均可顯著降低Han:SPRD大鼠腎重體重比(KW/BW)、囊腫指數(shù),改善腎功能。3組給藥組之間上述指標(biāo)沒(méi)有統(tǒng)計(jì)學(xué)差異。3、二甲雙胍、維格列汀、利格列汀都可以抑制WT9.12的增殖。三種藥物都存在濃度依賴性,在24小時(shí)、48小時(shí)、72小時(shí)三個(gè)時(shí)間節(jié)點(diǎn)50nM濃度的二甲雙胍對(duì)WT9.12細(xì)胞的增長(zhǎng)抑制率分別為34%,60%,74%；20nM維格列汀對(duì)WT9.12細(xì)胞的增長(zhǎng)抑制率分別為14%,20%,28%；1nM利格列汀對(duì)WT9.12細(xì)胞的增長(zhǎng)抑制率分別為79%,86%,93%。4、經(jīng)給藥后,給予二甲雙胍、維格列汀、利格列汀的模型大鼠腎組織中pAMPK的表達(dá)均顯著高于Ctrl組(P0.001),分別升高了2.7倍、3.5倍和5倍;而且維格列汀組顯著高于二甲雙胍組(3.5 vs.2.7,P0.001),而利格列汀組又顯著高于維格列汀組(5.1 vs 2.7,P0.001)。和對(duì)照組相比,二甲雙胍(4.5 vs 5.1,P=0.029)、維格列汀(3.9 vs 5.1,P0.001)、利格列汀(3.0 vs 5.1,P0.001)都可以使模型大鼠腎組織中過(guò)度活化的1nTOR被抑制,下游產(chǎn)物p70S6K表達(dá)量顯著下降；維格列汀組p70S6K蛋白表達(dá)量低于二甲雙胍組(3.9 vs4.5,P=0.045),利格列汀組低于維格列汀組(3.0vs.3.9,P=0.001)。結(jié)論本課題發(fā)現(xiàn)/DPKD患者和多囊腎模型大鼠腎組織中DPP4過(guò)表達(dá)。使用DPP4抑制劑,可以上調(diào)AMPK抑制過(guò)度激活的mTOR通路,抑制囊腫細(xì)胞增殖,延緩病情進(jìn)展。DPKD患者的DPP4過(guò)表達(dá)引起的mTOR過(guò)度激活可能是其發(fā)病機(jī)制之一,抑制DPP4活性,是治療ADPKD潛在的靶點(diǎn)。
[Abstract]:Background and objective: autosomal dominant polycystic kidney disease (Autosomal dominant polycystic kidney disease, ADPKD) is a human disease incidence of single gene hereditary kidney. The highest hormone replacement therapy of end-stage renal disease (ESRD) in 7-10% ADPKD patients. Although the disease has done a lot of research for 500 years, until today still can not the cure and the mechanism remains unknown. All races are not immune to ADPKD, 7-10% and ESRD. So the world, received renal replacement therapy (RRT) is the fourth leading cause of ADPKD. in different countries, the incidence of ESRD caused by ADPKD is different in Japan every year is 4.8 ppm, in the United States is the year 7.9 ppm, according to European countries every year 3.9 ppm to 15.3. in Denmark and the United States of Copenhagen [4] Olmsted epidemiological survey, the population under the age of 80, ADPKD The prevalence rate is 400 to 1000 points. One of the other studies since then in Europe and Japan show that different regions ADPKD prevalence rates from 543 to one in 4000. In view of the above research location, observation time, sampling methods, diagnostic criteria, family survey, population size are different, so the difference is big is understandable. However, from the autopsy report data for 1/339-1/492. is higher than 1/500, indicating a large number of patients in his life was not diagnosed.ADPKD from polycystic kidney disease 1 (Polycystic kidney disease 1 gene, PKD1) and polycystic kidney disease 2 (Polycystic kidney disease 2 gene, PKD2) two gene mutation caused the two gene encoding polycystins respectively -1 (Polycystin-1, PC1) and.2 (Polycystin-2, PC2, polycystins). The patients with PKD1 mutations accounted for 80 ~ 85%, PKD2 mutation patients accounted for 15-20%. called PKD3, after re analysis of related cases, Have basically ruled out the possibility of.PC1 and PC2 are interaction in renal tubular epithelial cells of primary cilia form complexes, which belong to the transient receptor potential (transient receptor potential, T P) is a non selective calcium channel family penetration in the.PC1 C terminal domain structure can be translocated to the nucleus, and act as the gene transcription coactivator.PC1 and PC2 subjected to mechanical stimulation in the cilia caused pathogenesis of.ADPKD Ca2+ within the moment is not yet clear, promising therapies focus on blocking the excessive activation of the mTOR pathway and cAMP pathway to delay the progression of the disease. Animal experiments showed that mTOR inhibitors (Bea Vimal S and sirolimus) improve the rodent animal model cystic kidney disease, the effect is very significant, but Bea Vimal S and are potent immunosuppressant sirolimus, may lead to fatal side-effects, and Clinical trials have not achieved good results. So we need to explore a more safe and effective means. A large number of reports confirmed that AMP activated protein kinase (AMP-activated protein kinase, AMPK) is one of the reasons: the down-regulation of mTOR pathway activation, by increasing the level of MPK can inhibit the excessive activation of the mTOR pathway system, and have achieved good results in in the animal model. By two inhibition of dipeptidyl peptidase 4 (dipeptidyl peptidase 4, DPP4) activity can increase the level of AMPK is no doubt, but can inhibit the excessive activation of the mTOR pathway to improve the ADPKD, whether the DPP4 expression of mTOR pathway leading to excessive activation of ADPKD patients and animal models, these two issues is no answer. The purpose of this study is to observe the renal tissue of ADPKD patients and animal in the presence of DPP4 expression, and the use of DPP4 inhibitors, whether can the same on AMPK inhibition The mTO activity of R, achieve the purpose of treatment of ADPKD. Methods: 1. To detect the expression of DPP4 in ADPKD patients and animal models: collect donor kidney tissue samples in patients with ADPKD and renal tissue transplantation, determination of expression of both DPP4 protein by Western blot technology, and compared the breeding of polycystic kidney; Han:SPRD rat model, identification the wild type (WT) and disease model (cy- / +), normal feeding to 12 weeks, the renal tissues, DPP4 protein expression was detected by using Western blot, compared to.2, the animal experiments to inhibit the activity of DPP4: drug intervention including AMPK activator (Metformin), metformin DPP4 inhibitor (Vildagliptin) and Leigh Glenn Dean Vee Glenn Dean (Linagliptin) breeding. Han:SPRD rat model of polycystic kidney, after the birth of identified wild type (WT) and model (cy-/+). The incidence of the disease model rats were randomly divided into control group (Ctrl) and metformin (MET) group, vildagliptin (VIG) group, linagliptin (LIG) group. After 3 groups of rats from birth 4 weeks after administration, in the 4/8/12 week blood check renal function, Twelfth Zhou Dai Xie cage was measured 24 h urine volume, and kill the animal, the two kidneys measured kidney weight / body weight ratio, protein extraction, pathology the line scanning.3 cells, experimental observation of effect of DPP4 on cell proliferation by human renal cyst lining epithelial cells WT9.12 were cultured. Vee Glenn Dean observed in different concentrations of metformin, using MTT method, under the action of linagliptin, 24 hours, 48 hours, 72 hours, the proliferation of.4 cells, inhibiting mechanism DPP4 activity in the treatment of ADPKD: different concentrations of metformin, Vee Glenn Dean, linagliptin treated WT9.12 cells, changes of protein content in Western intervention AMPK blot technology. The experiment from extraction of WT, Ctrl, MET, VIG, renal tissue in rats of LIG protein, AMPK was determined by Western blot technology, Akt, The content of p70S6K protein. Results: 1. Expression of DPP4 in renal tissue of ADPKD patients was significantly higher than that of donor kidney transplantation (1.97 vs.0.60, P=0.002), increased by about 3 times. The rat model of polycystic kidney (cy-/+) similar to the kidney, the expression of DPP4 increased by nearly 3 times the onset of kidney in model rats (7.49 vs 1.14, P=0.001.2), compared with the control group, metformin and vildagliptin and Leigh Glenn Dean could significantly decrease the Han:SPRD of rat kidney weight to body weight ratio (KW/BW), cyst index, improve renal function in.3 group administered group no significant difference between the index of.3, metformin, Vee Glenn Dean, linagliptin can inhibit the proliferation of WT9.12. Three kinds of drugs are concentration dependent, in 24 hours, 48 hours, three time node growth metformin concentration of 50nM for 72 hours on the WT9.12 cell inhibition rates were 34%, 60%, 74%; 20nM vildagliptin on WT9.12 cells increased The inhibition rates were 14%, 20%, 28%; Leigh Glenn Dean 1nM on WT9.12 cell growth inhibition rate were 79%, 86%, 93%.4 after treatment, metformin, Vee Glenn Dean, pAMPK expression of linagliptin in renal tissues in model rats were significantly higher than Ctrl group (P0.001), were increased by 2.7 times, 3.5 times and 5 times; and vildagliptin group was significantly higher than that of metformin group (3.5 vs.2.7, P0.001), while the Leigh Glenn Dean group was significantly higher than that of vildagliptin group (5.1 vs 2.7, P0.001). Compared with the control group, metformin (4.5 vs 5.1, P=0.029), Vee Glenn Dean (3.9 vs 5.1, P0.001, Leigh Glenn Dean) (3 vs 5.1, P0.001) can make the 1nTOR excessive activation of renal tissue in the rat model was inhibited, the expression of p70S6K downstream products decreased significantly; vildagliptin group p70S6K protein expression was lower than that of metformin group (3.9 vs4.5, P=0.045), linagliptin group was lower than that of group 3.0vs (vildagliptin .3.9, P=0.001). Conclusion: This study found that overexpression of DPP4 in renal tissue of rats with /DPKD and polycystic kidney model. Using the DPP4 inhibitor, can inhibit the mTOR pathway activated by upregulation of AMPK, inhibition of cyst cell proliferation, progression of.DPKD in patients with DPP4 overexpression caused by excessive activation of mTOR may be involved in its pathogenesis. Inhibition of DPP4 activity is potential therapeutic target for ADPKD.

【學(xué)位授予單位】：第二軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：R692.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 原愛(ài)紅,梅長(zhǎng)林;肝細(xì)胞生長(zhǎng)因子對(duì)ADPKD囊腫襯里上皮細(xì)胞合成細(xì)胞外基質(zhì)、基質(zhì)金屬蛋白酶及其抑制劑的作用(英文)[J];第二軍醫(yī)大學(xué)學(xué)報(bào);2003年01期

2 鄧博;丁峰;;常染色體顯性多囊腎病的新認(rèn)識(shí)[J];腎臟病與透析腎移植雜志;2013年02期

3 金訊波;張智宇;;常染色體顯性遺傳多囊腎病發(fā)病機(jī)制的研究現(xiàn)狀[J];泌尿外科雜志(電子版);2010年03期

4 戴兵,孫田美,梅長(zhǎng)林,劉沙勤,吳玉梅,沈?qū)W飛,王文靖,湯兵;角質(zhì)細(xì)胞生長(zhǎng)因子在常染色體顯性遺傳性多囊腎病腎組織中的表達(dá)[J];中華內(nèi)科雜志;2005年05期

5 馬吉芳;郝麗榮;李納琦;;在常染色體顯性遺傳性多囊腎病家系中血管緊張素轉(zhuǎn)換酶基因多態(tài)性作用的研究[J];哈爾濱醫(yī)藥;2010年02期

6 吳玉梅,梅長(zhǎng)林,孫田美,章建全,張玲,宋吉,戴兵,湯兵;胰島素樣生長(zhǎng)因子在常染色體顯性遺傳性多囊腎病發(fā)病中的作用[J];中華腎臟病雜志;2004年04期

7 戎殳;梅長(zhǎng)林;金修才;姜紅;牛曉萍;;常染色體顯性多囊腎病患者動(dòng)脈形態(tài)學(xué)、力學(xué)與部分功能性參數(shù)研究[J];中華腎臟病雜志;2006年08期

8 王文娟;李莉;楊建一;;常染色體顯性遺傳型多囊腎病的研究進(jìn)展[J];中國(guó)優(yōu)生與遺傳雜志;2011年01期

9 王禹霄;張承巍;薛繼強(qiáng);畢敏;李春媚;;利用與PKD1緊密連鎖的微衛(wèi)星多態(tài)性對(duì)黑龍江省漢族人群進(jìn)行ADPKD的癥前診斷[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2011年18期

10 畢敏,薛繼強(qiáng),張淼;ACE基因多態(tài)性與ADPKD的關(guān)系[J];哈爾濱醫(yī)科大學(xué)學(xué)報(bào);2005年01期

相關(guān)會(huì)議論文 前10條

1 賀津;王青松;葉建華;胡曉湘;李寧;;豬Pkd1基因的分子克隆與分析[A];中國(guó)遺傳學(xué)會(huì)模式生物與人類(lèi)健康研討會(huì)會(huì)議論文集[C];2010年

2 夏丹;邵四海;汪朔;沈柏華;汪超軍;潘昊;蔡松良;謝立平;;后腹腔鏡和開(kāi)放去頂減壓術(shù)治療[A];第十五屆全國(guó)泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

3 毛志國(guó);梅長(zhǎng)林;沈?qū)W飛;戴兵;湯兵;吳玉梅;張樹(shù)忠;趙海丹;;角質(zhì)細(xì)胞生長(zhǎng)因子在常染色體顯性遺傳性多囊腎病發(fā)病中的作用及機(jī)制研究[A];2007年浙滬兩地腎臟病學(xué)術(shù)年會(huì)資料匯編[C];2007年

4 方力;華興;于莉娜;;常染色體顯性多囊腎病癌變臨床病理分析[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2006年學(xué)術(shù)年會(huì)論文匯編[C];2006年

5 張巖;劉亞偉;沈?qū)W飛;趙海丹;梅長(zhǎng)林;;常染色體顯性多囊腎病患者與正常成人尿液的定量比較蛋白質(zhì)組學(xué)分析[A];“中華醫(yī)學(xué)會(huì)腎臟病學(xué)分會(huì)2004年年會(huì)”暨“第二屆全國(guó)中青年腎臟病學(xué)術(shù)會(huì)議”論文匯編[C];2004年

6 張小鹿;王怡;;常染色體顯性遺傳多囊腎病中西醫(yī)發(fā)病認(rèn)識(shí)及診斷研究進(jìn)展[A];第十一屆全國(guó)中西醫(yī)結(jié)合腎臟病學(xué)術(shù)會(huì)議論文匯編[C];2010年

7 戴兵;劉亞偉;熊錫山;丁濤;鄒祝英;梅長(zhǎng)林;;羅格列酮長(zhǎng)期治療ADPKD動(dòng)物模型Han:SPRD大鼠療效及安全性評(píng)價(jià)[A];中華醫(yī)學(xué)會(huì)腎臟病學(xué)分會(huì)2006年學(xué)術(shù)年會(huì)論文集[C];2006年

8 戴兵;劉亞偉;熊錫山;丁濤;鄒祝英;梅長(zhǎng)林;;羅格列酮長(zhǎng)期治療ADPKD動(dòng)物模型Han:SPRD大鼠的療效及安全性評(píng)價(jià)[A];2007年浙滬兩地腎臟病學(xué)術(shù)年會(huì)資料匯編[C];2007年

9 牛丹;呂晶;譚峰;張亞莉;尹愛(ài)平;馮學(xué)亮;;多囊腎致終末期腎病的腹膜透析治療[A];中華醫(yī)學(xué)會(huì)腎臟病學(xué)分會(huì)2006年學(xué)術(shù)年會(huì)論文集[C];2006年

10 戎殳;梅長(zhǎng)林;李青;吳玉梅;費(fèi)麗萍;吳靜娣;葉朝陽(yáng);趙學(xué)智;張玉強(qiáng);張黎明;;271例常染色體顯性多囊腎病患者臨床分析[A];“中華醫(yī)學(xué)會(huì)腎臟病學(xué)分會(huì)2004年年會(huì)”暨“第二屆全國(guó)中青年腎臟病學(xué)術(shù)會(huì)議”論文匯編[C];2004年

相關(guān)博士學(xué)位論文 前10條

1 程明;二肽基肽酶4在常染色體顯性多囊腎病發(fā)病中的機(jī)制與作用研究[D];第二軍醫(yī)大學(xué);2016年

2 劉沙勤;角質(zhì)細(xì)胞生長(zhǎng)因子在ADPKD腎囊腫組織中的表達(dá)及對(duì)囊腫襯里上皮細(xì)胞增殖作用的研究[D];第二軍醫(yī)大學(xué);2002年

3 周玉坤;多囊蛋白—2在腎組織中的表達(dá)及在ADPKD發(fā)病機(jī)制中的作用研究[D];第二軍醫(yī)大學(xué);2003年

4 戎殳;常染色體顯性多囊腎病動(dòng)脈功能研究[D];第二軍醫(yī)大學(xué);2007年

5 薛澄;常染色體顯性多囊腎病遺傳因素對(duì)疾病進(jìn)展的影響及治療策略的薈萃分析[D];第二軍醫(yī)大學(xué);2014年

6 崔心剛;腎移植前后常染色體顯性遺傳多囊腎的臨床與基礎(chǔ)研究[D];第二軍醫(yī)大學(xué);2004年

7 鄭瑞英;抗多囊蛋白-1單克隆抗體的制備及在ADPKD發(fā)病機(jī)理研究中的應(yīng)用[D];第二軍醫(yī)大學(xué);2000年

8 王文靖;富含半胱氨酸酸性分泌糖蛋白在常染色體顯性多囊腎病發(fā)病中的作用研究[D];第二軍醫(yī)大學(xué);2005年

9 張樹(shù)忠;漢族人常染色體顯性遺傳性多囊腎病1型致病基因突變檢測(cè)體系的建立及應(yīng)用[D];第二軍醫(yī)大學(xué);2003年

10 張殿勇;中國(guó)漢族人PKD2基因突變和多態(tài)性檢測(cè)[D];第二軍醫(yī)大學(xué);2003年

相關(guān)碩士學(xué)位論文 前10條

1 韓樂(lè)天;骨橋蛋白在ADPKD腎臟中的表達(dá)及意義[D];山東大學(xué);2010年

2 陳輯;應(yīng)用基因芯片技術(shù)對(duì)ADPKD進(jìn)行基因診斷[D];山東大學(xué);2006年

3 秦均珍;應(yīng)用微衛(wèi)星DNA對(duì)常染色體顯性遺傳性多囊腎病（ADPKD）進(jìn)行癥狀前檢測(cè)及產(chǎn)前診斷的研究[D];廣西醫(yī)科大學(xué);2014年

4 王文儀;Shh信號(hào)通路在ADPKD發(fā)病機(jī)制中的作用[D];北京協(xié)和醫(yī)學(xué)院;2012年

5 葛守一;HMG GoA還原酶抑制劑對(duì)ADPKD囊腫襯里上皮細(xì)胞增殖抑制和凋亡誘導(dǎo)的研究[D];第二軍醫(yī)大學(xué);2001年

6 寧豪;COX-2在ADPKD腎臟致密斑和足細(xì)胞中的表達(dá)及意義[D];山東大學(xué);2008年

7 湯兵;轉(zhuǎn)化生長(zhǎng)因子β1在人常染色體顯性多囊腎病發(fā)病中的意義[D];第二軍醫(yī)大學(xué);2004年

8 闕新祥;TGF-β1和VEGF在人多囊腎發(fā)病機(jī)制中的表達(dá)研究[D];山東大學(xué);2015年

9 吳玉梅;胰島素樣生長(zhǎng)因子在常染色體顯性遺傳性多囊腎病發(fā)病中的作用研究[D];第二軍醫(yī)大學(xué);2003年

10 邵建國(guó);CTGF和TGF-β1在ADPKD腎臟中的表達(dá)及意義[D];山東大學(xué);2012年

，

本文編號(hào)：1480011